|
1
|
Saphner T, Tormey DC and Gray R: Annual
hazard rates of recurrence for breast cancer after primary therapy.
J Clin Oncol. 14:2738–2746. 1996.PubMed/NCBI View Article : Google Scholar
|
|
2
|
Perou CM, Sørlie T, Eisen MB, van de Rijn
M, Jeffrey SS, Rees CA, Pollack JR, Ross DT, Johnsen H, Akslen LA,
et al: Molecular portraits of human breast tumours. Nature.
406:747–752. 2000.PubMed/NCBI View
Article : Google Scholar
|
|
3
|
Mohr AM and Mott JL: Overview of microRNA
biology. Semin Liver Dis. 35:3–11. 2015.PubMed/NCBI View Article : Google Scholar
|
|
4
|
Blenkiron C, Goldstein LD, Thorne NP,
Spiteri I, Chin SF, Dunning MJ, Barbosa-Morais NL, Teschendorff AE,
Green AR, Ellis IO, et al: MicroRNA expression profiling of human
breast cancer identifies new markers of tumor subtype. Genome Biol.
8(R214)2007.PubMed/NCBI View Article : Google Scholar
|
|
5
|
Iorio MV, Ferracin M, Liu CG, Veronese A,
Spizzo R, Sabbioni S, Magri E, Pedriali M, Fabbri M, Campiglio M,
et al: MicroRNA gene expression deregulation in human breast
cancer. Cancer Res. 65:7065–7070. 2005.PubMed/NCBI View Article : Google Scholar
|
|
6
|
Amini S, Abak A, Sakhinia E and Abhari A:
MicroRNA-221 and microRNA-222 in common human cancers: Expression,
function, and triggering of tumor progression as a key modulator.
Lab Med. 50:333–347. 2019.PubMed/NCBI View Article : Google Scholar
|
|
7
|
Stinson S, Lackner MR, Adai AT, Yu N, Kim
HJ, O'Brien C, Spoerke J, Jhunjhunwala S, Boyd Z, Januario T, et
al: miR-221/222 targeting of trichorhinophalangeal 1 (TRPS1)
promotes epithelial-to-mesenchymal transition in breast cancer. Sci
Signal. 4(pt5)2011.PubMed/NCBI View Article : Google Scholar
|
|
8
|
Li B, Lu Y, Yu L, Han X, Wang H, Mao J,
Shen J, Wang B, Tang J, Li C and Song B: miR-221/222 promote cancer
stem-like cell properties and tumor growth of breast cancer via
targeting PTEN and sustained Akt/NF-κB/COX-2 activation. Chem Biol
Interact. 277:33–42. 2017.PubMed/NCBI View Article : Google Scholar
|
|
9
|
Abak A, Amini S, Sakhinia E and Abhari A:
MicroRNA-221: biogenesis, function and signatures in human cancers.
Eur Rev Med Pharmacol Sci. 22:3094–3117. 2018.PubMed/NCBI View Article : Google Scholar
|
|
10
|
Li S, Li Q, Lü J, Zhao Q, Li D, Shen L,
Wang Z, Liu J, Xie D, Cho WC, et al: Targeted inhibition of
miR-221/222 promotes cell sensitivity to cisplatin in
triple-negative breast cancer MDA-MB-231 cells. Front Genet.
10(1278)2020.PubMed/NCBI View Article : Google Scholar
|
|
11
|
Shen H, Lin Z, Shi H, Wu L, Ma B, Li H,
Yin B, Tang J, Yu H and Yin X: MiR-221/222 promote migration and
invasion, and inhibit autophagy and apoptosis by modulating ATG10
in aggressive papillary thyroid carcinoma. 3 Biotech.
10(339)2020.PubMed/NCBI View Article : Google Scholar
|
|
12
|
Tian F, Wang P, Lin D, Dai J, Liu Q, Guan
Y, Zhan Y, Yang Y, Wang W, Wang J, et al: Exosome-delivered
miR-221/222 exacerbates tumor liver metastasis by targeting SPINT1
in colorectal cancer. Cancer Sci. 112:3744–3755. 2021.PubMed/NCBI View Article : Google Scholar
|
|
13
|
Liu C, Li N, Liu G and Feng X: Annexin A3
and cancer. Oncol Lett. 22(834)2021.PubMed/NCBI View Article : Google Scholar
|
|
14
|
Kim JY, Jung EJ, Park HJ, Lee JH, Song EJ,
Kwag SJ, Park JH, Park T, Jeong SH, Jeong CY, et al:
Tumor-suppressing effect of silencing of annexin A3 expression in
breast cancer. Clin Breast Cancer. 18:e713–e719. 2018.PubMed/NCBI View Article : Google Scholar
|
|
15
|
Liu Q, Wang S, Pei G, Yang Y, Min X, Huang
Y and Liu J: Impact analysis of miR-1253 on lung cancer progression
through targeted regulation of ANXA3. Cancer Manag Res.
13:1767–1776. 2021.PubMed/NCBI View Article : Google Scholar
|
|
16
|
Amin MB, Edge SB, Greene FL, Byrd DR,
Brookland RK, Washington MK, Gershenwald JE, Compton CC, Hess KR,
et al: AJCC Cancer Staging Manual. 8th edition. Springer, New York,
NY, 2017.
|
|
17
|
Livak KJ and Schmittgen TD: Analysis of
relative gene expression data using real-time quantitative PCR and
the 2(-Delta Delta C(T)) method. Methods. 25:402–408.
2021.PubMed/NCBI View Article : Google Scholar
|
|
18
|
He L, Du Z, Xiong X, Ma H, Zhu Z, Gao H,
Cao J, Li T, Li H, Yang K, et al: Targeting androgen receptor in
treating HER2 positive breast cancer. Sci Rep.
7(14584)2017.PubMed/NCBI View Article : Google Scholar
|
|
19
|
Eissa S, Matboli M, Sharawy A and
El-Sharkawi F: Prognostic and biological significance of
microRNA-221 in breast cancer. Gene. 574:163–167. 2015.PubMed/NCBI View Article : Google Scholar
|
|
20
|
Hwang MS, Yu N, Stinson SY, Yue P, Newman
RJ, Allan BB and Dornan D: MiR-221/222 targets adioponectin
receptor 1 to promote the epithelial -to mesenchymal transition in
breast cancer. PLoS One. 11(e66502)2013.PubMed/NCBI View Article : Google Scholar
|
|
21
|
Li Y, Liang C, Ma H, Zhao Q, Lu Y, Xiang
Z, Li L, Qin J, Chen Y, Cho WC, et al: miR-221/222 promotes S-phase
entry and cellular migration in control of basal-like breast
cancer. Molecules. 30:7122–7137. 2014.PubMed/NCBI View Article : Google Scholar
|
|
22
|
Harper JW and Adams PD: Cyclin-dependent
kinases. Chem Rev. 101:2511–2526. 2001.PubMed/NCBI View Article : Google Scholar
|
|
23
|
Malumbres M: Cyclin-dependent kinases.
Genome Biol. 15(122)2014.PubMed/NCBI View
Article : Google Scholar
|
|
24
|
Bertoli C, Skotheim JM and De Bruin RA:
Control of cell cycle transcription during G1 and S phase. Nat Rev
Mol Cell Biol. 14:518–528. 2013.PubMed/NCBI View Article : Google Scholar
|
|
25
|
Kovatsi L, Georgiou E, Ioannou A,
Haitoglou C, Tzimagiorgis G, Tsoukali H and Kouidou S: p16 promoter
methylation in Pb2+ -exposed individuals. Clin Toxicol
(Phila). 48:124–128. 2010.PubMed/NCBI View Article : Google Scholar
|
|
26
|
Ghafouri-Fard S, Shoorei H, Anamag FT and
Taheri M: The role of non-coding RNAs in controlling cell cycle
related proteins in cancer cells. Front Oncol.
30(608975)2020.PubMed/NCBI View Article : Google Scholar
|
|
27
|
Mishra PJ: The miR-drug resistance
connection: A new era of personalized medicine using noncoding RNA
begins. Pharmacogenomics. 13:1321–1324. 2012.PubMed/NCBI View Article : Google Scholar
|
|
28
|
Ma J, Dong C and Ji C: MicroRNA and drug
resistance. Cancer Gene Ther. 17:523–531. 2010.PubMed/NCBI View Article : Google Scholar
|
|
29
|
Zheng T, Wang J, Chen X and Liu L: Role of
microRNA in anticancer drug resistance. Int J Cancer. 126:2–10.
2010.PubMed/NCBI View Article : Google Scholar
|
|
30
|
Rao X, Di Leva G, Li M, Fang F, Devlin C,
Hartman-Frey C, Burow ME, Ivan M, Croce CM and Nephew KP:
MicroRNA-221/222 confers breast cancer fulvestrant resistance by
regulating multiple signaling pathways. Oncogene. 30:1082–1097.
2011.PubMed/NCBI View Article : Google Scholar
|
|
31
|
Garofalo M, Di Leva G, Romano G, Nuovo G,
Suh SS, Ngankeu A, Taccioli C, Pichiorri F, Alder H, Secchiero P,
et al: miR-221&222 regulate trail resistance and enhance
tumorigenicity through PTEN and TIMP3 downregulation. Cancer Cell.
16:498–509. 2009.PubMed/NCBI View Article : Google Scholar
|
|
32
|
He C, Dong X, Zhai B, Jiang X, Dong D, Li
B, Jiang H, Xu S and Sun X: MiR-21 mediates sorafenib resistance of
hepatocellular carcinoma cells by inhibiting autophagy via the
PTEN/Akt pathway. Oncotarget. 6:28867–28881. 2015.PubMed/NCBI View Article : Google Scholar
|
|
33
|
Yan X, Yin J, Yao H, Mao N, Yang Y and Pan
L: Increased expression of annexin A3 is a mechanism of platinum
resistance in ovarian cancer. Cancer Res. 70:1616–1624.
2010.PubMed/NCBI View Article : Google Scholar
|
|
34
|
Tong SW, Yang YX, Hu HD, An X, Ye F, Hu P,
Ren H, Li SL and Zhang DZ: Proteomic investigation of
5-fluorouracil resistance in a human hepatocellular carcinoma cell
line. J Cell Biochem. 113:1671–1680. 2012.PubMed/NCBI View Article : Google Scholar
|
|
35
|
Pénzváltó Z, Tegze B, Szász AM,
Sztupinszki Z, Likó I, Szendrői A, Schäfer R and Győrffy B:
Identifying resistance mechanisms against five tyrosine kinase
inhibitors targeting the ERBB/RAS pathway in 45 cancer cell lines.
PLoS One. 8(e59503)2013.PubMed/NCBI View Article : Google Scholar
|
|
36
|
Du R, Liu B, Zhou L, Wang D, He X, Xu X,
Zhang L, Niu C and Liu S: Downregulation of annexin A3 inhibits
tumor metastasis and decreases drug resistance in breast cancer.
Cell Death Dis. 9(126)2018.PubMed/NCBI View Article : Google Scholar
|
|
37
|
Zhu S, Li Y, Wang Y, Cao J, Li X, Wang J
and Wang X: Efficacy of neoadjuvant chemotherapy and annexin A3
expression in breast cancer. J BUON. 24:522–528. 2019.PubMed/NCBI
|
